跳至內容

索非布韋/達卡他韋

維基百科,自由的百科全書
索非布韋/達卡他韋
Sovodak 60/400
組成
達卡他韋NS5A英語Hepatitis C virus nonstructural protein 5B 抑制劑
索非布韋NS5B英語Hepatitis C virus nonstructural protein 5B (RNA聚合酶) 抑制劑
臨床資料
商品名英語Drug nomenclatureDarvoni,[1] Sovodak
給藥途徑Oral
識別資訊
CAS號2306918-02-3

索非布韋/達卡他韋(daclatasvir/sofosbuvir,SOF/DCV)用於治療C型肝炎複方藥[2]。它是第一線治療,對所有亞型均有效[3]。療效 90% 以上[2]。適用年齡至少需 3 歲以上[4]。通常每天口服一次,連續服用 12 周,可以服用一粒複方藥或兩種各別成份的藥物[5] [2]

常見副作用包括頭痛、疲倦、噁心和腹痛[5]。嚴重副作用並不常見[5]。雖未發現孕期使用有害,但研究尚不充分[6] [7]。此藥物內含達卡他韋(一種病毒非結構蛋白5A英語Hepatitis C virus nonstructural protein 5A抑制劑) [8]索非布韋(一種病毒非結構蛋白5B英語Hepatitis C virus nonstructural protein 5BRNA聚合酶核苷酸抑制劑)[9]

至 2022 年為止,它是開發中國家最常用的C型肝炎療法[3]。但這個組合藥物未在美國取得醫療使用許可,在美國於 2019 年停止銷售達卡他韋[10]。名列世界衛生組織基本藥物標準清單[11]

參考文獻

[編輯]
  1. ^ Home. Darvoni - Beacon Medicare Limited. 
  2. ^ 2.0 2.1 2.2 Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepatic Medicine: Evidence and Research. 2016, 8: 21–26. PMC 4786064可免費查閱. PMID 27019602. doi:10.2147/HMER.S62014. 
  3. ^ 3.0 3.1 Hepatitis C. www.who.int. [2 December 2022]. (原始內容存檔於26 May 2020) (英語). 
  4. ^ WHO publishes updated guidance on hepatitis C infection – with new recommendations on treatment of adolescents and children, simplified service delivery and diagnostics. www.who.int. [2 December 2022]. (原始內容存檔於6 October 2022) (英語). 
  5. ^ 5.0 5.1 5.2 Application for Inclusion of Sofosbuvir/Daclatasvir on the WHO Model List of Essential Medicines for Children (EMLc) (PDF). [2 December 2022]. (原始內容存檔 (PDF)於2 December 2022). 
  6. ^ Daclatasvir (Daklinza) Use During Pregnancy. Drugs.com. [2 December 2022]. (原始內容存檔於6 December 2021) (英語). 
  7. ^ Sofosbuvir (Sovaldi) Use During Pregnancy. Drugs.com. [2 December 2022]. (原始內容存檔於5 February 2020) (英語). 
  8. ^ Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC). Electronic Medicines Compendium. September 2016. (原始內容存檔於2016-11-09). 
  9. ^ Sovaldi 400 mg film coated tablets - Summary of Product Characteristics. UK Electronic Medicines Compendium. September 2016 [10 November 2016]. (原始內容存檔於10 November 2016). 
  10. ^ Abraham, GM; Obley, AJ; Humphrey, LL; Qaseem, A; Scientific Medical Policy Committee of the American College of, Physicians; Centor, RM; Akl, E; Forceia, MA; Haeme, R; Hamilton, PG; Hood, GA. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians.. Annals of internal medicine. January 2021, 174 (1): 98-100. PMID 33017566. doi:10.7326/M19-3860. 
  11. ^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.